Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Resolve Bio Sciences GmbH maintains 1 pending office action located within the Biotechnology & Pharmaceuticals technology area. The prosecution activity is limited to 1 distinct examiner and 1 distinct art unit, which reflects a narrow point of contact with the patent office. This concentration means that the company's current patent outcomes are subject to the interpretation of a single administrative unit. Such a focused portfolio allows for a specialized prosecution strategy but provides no internal baseline for comparing examiner behavior across the company's filings.
The busiest examiner identified in the data is BELLAH, JEFFREY LAWRENCE, who is currently processing 1 pending office action. As this examiner manages the only active action for the portfolio, their individual examination style will dictate the immediate trajectory of the company's intellectual property in the Biotechnology & Pharmaceuticals sector. Practitioners should focus on the specific history of this 1 distinct examiner to navigate the current administrative requirements. The reliance on 1 distinct art unit further emphasizes the need for a targeted approach to the current administrative requirements.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BELLAH, JEFFREY LAWRENCE | 1 | 66.7% | +100.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18344324 | HIGH RESOLUTION MULTIPLEX METHOD FOR DETECTING AT LEAST TWO TARGETS WITH A DISTANCE OF BEYOND THE DIFFRACTION LIMIT IN A SAMPLE | BELLAH, JEFFREY LAWRENCE | 50d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18344324 | HIGH RESOLUTION MULTIPLEX METHOD FOR DETECTING AT LEAST TWO TARGETS WITH A DISTANCE OF BEYOND THE DIFFRACTION LIMIT IN A SAMPLE | BELLAH, JEFFREY LAWRENCE | 50d overdue |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18344324 | HIGH RESOLUTION MULTIPLEX METHOD FOR DETECTING AT LEAST TWO TARGETS WITH A DISTANCE OF BEYOND THE DIFFRACTION LIMIT IN A SAMPLE | BELLAH, JEFFREY LAWRENCE | 1683 | §103§112Other | Final Rejection | 50d overdue | Pending | Jun 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialResolve Bio Sciences GmbH has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Jeffrey Lawrence Bellah has the most, with 1 of Resolve Bio Sciences GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.